Protection against ulcerative colitis and colorectal cancer by evodiamine via anti-inflammatory effects

Evodiamine (Evo) is an alkaloid that can be extracted from the berry fruit Evodia rutaecarpa and has been reported to exert various pharmacological effects, such as antidiarrheal, antiemetic and antiulcer effects. In vivo, the potential effects of Evo were investigated in a mouse model of dextran sodium sulfate (DSS)-induced ulcerative colitis (UC) and in adenomatous polyposis coli (Apc)(MinC)/Gpt C57BL/6 mice with colorectal cancer (CRC), where the latter harbours a point-mutation in the Apc gene. Evo suppressed the degree of weight loss and colon shortening induced by DSS, decreased the disease activity index value and ameliorated the pathological alterations in the colon of mice with UC as examined via H & E staining of colon tissues. In addition, Evo decreased the number and size of colonic tumors in Apc(MinC)/Gpt mice. Proteomics (colon tissues), ELISA (colon tissues and serum) and western blotting (colon tissues) results revealed that Evo inhibited NF-kappa B to mediate the levels of various cytokines, including, in the DSS-induced UC model, IL-1 beta, IL-2, IL-6, IL-8, TNF-alpha, IFN-gamma (ELISA of colon tissues and serum), NF-kappa B, IKK alpha+beta, I kappa B alpha, S100a9, TLR4 and MyD88 (western blotting of colon tissues), and, in the colorectal cancer model, IL-1 beta, IL-2, IL-6, IL-15, IL-17, IL-22, TNF-alpha (ELISA of colon tissues and serum), NF-kappa B, IKK alpha+beta, I kappa B alpha and S100a9 (western blotting of colon tissues), to achieve its anti-inflammatory and antitumor effects. In vitro, Evo also reduced the viability of the colon cancer cell line SW480, inhibited mitochondrial membrane potential (MMP detection), caused G(2)/M-phase arrest (cell cycle detection) and suppressed the translocation of phosphorylated-NF-kappa B from the cytoplasm into the nucleus (immunofluorescence of p-NF-kappa B). Theoretical evidence (MD simulations) suggest that Evo may bind to the ordered domain (alpha-helix) of NF-kappa B to influence this protein. The protein secondary structure changes were analyzed by the cpptraj module in Amber. In addition, these data provide experimental evidence that Evo may be an effective agent for treating UC and CRC.